PARACETAMOL 250MG + PHENYLEPHRINE 5MG + CHLORPHENIRAMINE MALEATE 2MG is a multi-component pharmaceutical formulation containing Paracetamol, Phenylephrine, and Chlorpheniramine Maleate as active pharmaceutical ingredients. The composition combines three ingredients in defined quantities and can be developed into an appropriate oral dosage form according to the approved product specification.
The stated composition contains Paracetamol 250MG, Phenylephrine 5MG, and Chlorpheniramine Maleate 2MG. Because these ingredients have different physicochemical characteristics and are present at different concentrations, formulation development requires careful consideration of material properties, compatibility, blend uniformity, and dosage-form performance.
Depending on the finalized formulation, suitable pharmaceutical excipients may be incorporated to achieve the required physical and manufacturing characteristics. These can include diluents, binders, disintegrants, lubricants, glidants, stabilizers, sweeteners, flavoring agents, buffering components, or other formulation-specific ingredients.
Preformulation studies may evaluate particle size, bulk density, flowability, moisture content, solubility, compressibility, and compatibility with selected excipients. These evaluations help establish an appropriate formulation and manufacturing process.
Maintaining consistency across the complete batch is an important quality objective, particularly because the three active ingredients are incorporated at different quantities.
The development of PARACETAMOL 250MG + PHENYLEPHRINE 5MG + CHLORPHENIRAMINE MALEATE 2MG requires evaluation of the individual properties of each active pharmaceutical ingredient. Paracetamol is present at the highest stated quantity, while Phenylephrine and Chlorpheniramine Maleate are incorporated at lower levels.
Differences in particle size, density, flowability, and moisture characteristics can influence the behavior of the formulation during processing. Therefore, controlled raw-material preparation may include appropriate sieving, milling, or other particle-size-management procedures where required.
Low-concentration ingredients require particular attention during blending. Premixing or geometric dilution may be used during formulation development to improve the distribution of Phenylephrine and Chlorpheniramine Maleate throughout the larger powder mass.
Excipient compatibility studies can also be performed to evaluate whether the selected formulation components remain physically and chemically compatible. These studies may examine parameters such as appearance, moisture behavior, chemical stability, and other relevant characteristics.
The blending sequence and mixing conditions are established during development. Equipment type, batch loading, mixing time, and order of addition can influence blend uniformity and therefore need appropriate process control.
Representative sampling can be used to verify the homogeneity of the bulk formulation before it proceeds to the final dosage-form manufacturing stage.
The manufacturing process begins with the receipt, identification, sampling, testing, and release of approved raw materials. Paracetamol, Phenylephrine, Chlorpheniramine Maleate, and selected excipients are accurately dispensed according to the authorized master manufacturing formula.
The physical preparation of raw materials may include sieving or other suitable processes to improve particle-size consistency. Depending on the final dosage form and powder characteristics, direct compression, granulation, or another suitable pharmaceutical manufacturing process may be selected.
During blending, the active ingredients are gradually incorporated into the excipient system according to a defined manufacturing sequence. Controlled mixing helps achieve a homogeneous formulation while maintaining appropriate powder flow and processing characteristics.
If granulation is selected, the granulation, drying, sizing, and lubrication parameters are established according to formulation-development studies. The resulting material is then evaluated before compression or other final dosage-form processing.
For tablet formulations, compression parameters such as tablet weight, thickness, hardness, compression force, and machine speed can be monitored throughout production. These controls help maintain consistency between individual units.
In-process checks may also include appearance, weight variation, physical dimensions, hardness, and other relevant parameters. Manufacturing conditions are controlled to minimize variation and maintain the established product specifications.
Quality control of PARACETAMOL 250MG + PHENYLEPHRINE 5MG + CHLORPHENIRAMINE MALEATE 2MG involves chemical, physical, and, where applicable, microbiological evaluation according to the approved product specification.
Analytical testing may include identification and assay of all three active pharmaceutical ingredients. Additional testing may include related substances, uniformity of dosage units, dissolution, disintegration, average weight, hardness, friability, moisture content, appearance, and other applicable quality attributes.
Because three active ingredients are present at different concentrations, validated analytical procedures should be capable of accurately identifying and quantifying each component. The analytical method should provide suitable sensitivity for the lower-strength ingredients.
Uniformity testing is important for confirming consistent distribution of active components between individual dosage units. Representative sampling and appropriate laboratory procedures help provide meaningful batch-quality information.
Physical quality testing may evaluate color, shape, surface appearance, dimensions, hardness, friability, and other characteristics relevant to the selected dosage form.
Quality assurance activities complement laboratory testing. Raw-material qualification, equipment calibration, process validation, controlled manufacturing documentation, environmental monitoring, deviation management, change control, and batch-release procedures all contribute to an organized pharmaceutical quality system.
Stability studies are conducted to evaluate how PARACETAMOL 250MG + PHENYLEPHRINE 5MG + CHLORPHENIRAMINE MALEATE 2MG maintains its established quality attributes during storage.
Depending on the dosage form, stability testing may monitor appearance, assay, degradation-related characteristics, dissolution, disintegration, moisture content, physical properties, and other relevant parameters at predetermined intervals.
Packaging selection is an important part of stability management. Pharmaceutical-grade blister packs, strip packs, bottles, or other suitable container-closure systems may be selected according to the finalized dosage form and product specifications.
The packaging system should provide appropriate protection against environmental exposure and mechanical stress during storage and transportation. Container-closure compatibility may also be evaluated to ensure that the formulation remains stable within the selected packaging configuration.
Packaging operations should maintain accurate unit count or fill quantity, appropriate sealing, proper coding, and clear product identification. Batch number, manufacturing information, expiry details, and other applicable labeling requirements should be incorporated according to regulatory specifications.
Stability data can help support the selection of appropriate packaging materials and the establishment of suitable shelf-life conditions.
PARACETAMOL 250MG + PHENYLEPHRINE 5MG + CHLORPHENIRAMINE MALEATE 2MG can be incorporated into a diversified pharmaceutical portfolio containing different strengths, dosage forms, and combination formulations. Its development requires controlled raw-material handling, appropriate formulation design, accurate blending, consistent manufacturing, analytical testing, and protective packaging.
A professional pharmaceutical product-development system coordinates formulation scientists, production personnel, quality-control laboratories, quality-assurance teams, packaging specialists, and regulatory departments. Clearly defined specifications and documented processes help maintain consistency from raw-material procurement through finished-product release.
For formulations containing active ingredients at significantly different strengths, particular attention should be given to dispensing accuracy, premixing strategies, blend uniformity, representative sampling, and analytical sensitivity. These factors contribute to consistent finished-product quality.
For pharmaceutical businesses expanding their PCD Pharma Franchise portfolio, this combination can be included within a broader range of tablets, capsules, syrups, suspensions, drops, creams, and other pharmaceutical formulations. Consistent manufacturing practices, validated testing procedures, stability evaluation, suitable packaging, and systematic quality management can support the development of a professional and reliable pharmaceutical product portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech